Welcome to our dedicated page for Savara SEC filings (Ticker: SVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Savara Inc. filings document a clinical-stage biopharmaceutical issuer focused on rare respiratory diseases and its development of molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis. The record includes Nasdaq-listed common stock disclosures, Regulation FD corporate presentations, clinical and regulatory updates, operating and financial results, and material-event reports tied to business operations.
Recent filings also cover definitive proxy materials, board and compensation matters, shareholder voting matters, lease obligations, and debt arrangements under a loan and security agreement. These disclosures describe Savara's capital structure, financing covenants, material agreements, governance practices and corporate reporting obligations.
Savara Inc's Chief Financial Officer, David Lowrance, reported two transactions in the company’s common stock. On December 14, 2025, 62,960 shares were disposed of at $6.92 per share, representing shares withheld by Savara to cover tax liabilities from the vesting of previously awarded restricted stock units, leaving him with 318,045 shares owned directly.
On December 16, 2025, he reported a bona fide gift of 32,000 shares to The McCallie School at a reported price of $0.00 per share, after which he directly owned 286,045 shares of Savara common stock. He does not have voting or investment power over the shares held by The McCallie School.
Savara Inc director and chief executive officer Matthew Pauls reported two changes in his common stock holdings. On 12/14/2025, 195,705 shares of common stock were disposed of at $6.92 per share, representing shares withheld by the company to cover tax liabilities arising from the vesting of previously awarded restricted stock units. After this, he held 1,317,045 shares.
On 12/16/2025, he reported a disposition of 128,995 common shares at a price of $0.00, reflecting a transfer to the GP 2024 Trust, U/A dated 12/20/2024, for no consideration. He is not a trustee of the trust and does not retain investment or voting control over those shares, and disclaims beneficial ownership except to the extent of any pecuniary interest. Following this gift, he beneficially owns 1,188,050 Savara common shares directly.
Savara Inc reported an insider equity transaction by its Chief Operating Officer, Robert Lutz. On 12/14/2025, the company withheld 67,760 shares of Savara common stock at $6.92 per share to cover his tax obligations arising from the vesting of previously awarded restricted stock units.
After this tax-related share withholding, Robert Lutz directly beneficially owned 293,977 shares of Savara common stock.
Savara Inc's chief legal officer reported an equity transaction involving company stock. On 12/14/2025, Savara withheld 39,350 shares of common stock at $6.92 per share to satisfy the reporting person's tax liability arising from the vesting of previously awarded restricted stock units. After this tax withholding transaction, the officer beneficially owned 519,232 shares of Savara common stock directly.
Savara Inc chief business officer Anne Erickson reported a tax-related disposition of common stock. On 12/14/2025, 62,960 shares of Savara common stock were withheld by the company at a price of $6.92 per share to satisfy her tax liability upon vesting of previously awarded restricted stock units. After this withholding transaction, she directly beneficially owns 371,712 Savara shares.
Savara Inc. director Richard Hawkins reported an equity award of 40,000 restricted stock units (RSUs) of Savara common stock dated December 9, 2025. The RSUs vest in full on December 9, 2026, provided he continues his service with the company, and each RSU represents a right to receive one share of common stock. He has elected to defer delivery of the vested shares until after his service with Savara ends. Following this grant, he beneficially owns 161,326 shares of Savara common stock in direct ownership.
Savara Inc director David Ramsay reported the acquisition of 40,000 restricted stock units (RSUs) tied to the company’s common stock on December 9, 2025. The RSUs vest in full on December 9, 2026, provided he continues to serve with Savara, and each RSU represents a contingent right to receive one share of common stock. The transaction price was listed as $0.00, indicating no cash was paid for the award. Following this grant, Ramsay beneficially owns 2,553,642 shares of Savara common stock in direct ownership.
Savara Inc director Joseph S. McCracken reported acquiring 40,000 shares of common stock on December 9, 2025 at a reported price of $0.00 per share. Following this equity award, he beneficially owns 300,837 shares of Savara common stock directly.
The 40,000 shares are described as restricted stock units (RSUs) that vest in full on December 9, 2026, if he continues his service with the company. Each RSU represents a contingent right to receive one share of common stock, and he has elected to defer receipt of these shares so that they will be delivered after his service with Savara ends.
Savara Inc. (SVRA) director reports stock option exercise. A Savara director filed a Form 4 reporting the exercise of a stock option for 5,860 shares of common stock on 11/14/2025 at an exercise price of $1.46 per share. After this transaction, the director directly holds 121,326 shares of Savara common stock. The related stock option, which vested in twelve equal quarterly installments beginning on March 15, 2016, has now been fully exercised, leaving 0 derivative securities beneficially owned.
Savara Inc. (SVRA) launched a primary offering of 23,809,524 shares of common stock and pre-funded warrants to purchase 7,142,857 shares. The shares are priced at $4.20 and the pre-funded warrants at $4.199 with a $0.001 exercise price. Gross proceeds are $129,992,857, with underwriting discounts of $7,800,000, for net proceeds before expenses of $122,192,857. The company estimates net proceeds of about $121.7 million after expenses.
The underwriters have a 30‑day option to buy up to 4,642,857 additional shares; if fully exercised, net proceeds before expenses would be $140,522,857. Savara plans to use the funds for working capital and general corporate purposes, including advancing MOLBREEVI toward regulatory approval, building commercialization infrastructure and supply, and launch preparation in the U.S. and EU.
The company also disclosed a purchase and sale agreement with RTW Investments under which Savara would receive $75.0 million upon FDA approval of MOLBREEVI on or before March 31, 2027, in exchange for tiered royalties on U.S. net sales, capped at $187.5 million.